Intravitreal bevacizumab to treat retinopathy of prematurity in 865 eyes: a study to determine predictors of primary treatment failure and recurrence

Author:

Fadakar Kaveh,Mehrabi Bahar MohammadrezaORCID,Riazi-Esfahani Hamid,Azarkish Afsaneh,Farahani Afsar Dastjani,Heidari Mostafa,Bazvand Fatemeh

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology

Reference39 articles.

1. Gillbert C, Muhit M (2008) Twenty years of childhood blindness: What have we learnt? Community Eye Heal J. 21(67):46–47. Accessed December 16, 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2580065/

2. Hartnett ME, Penn JS (2012) Mechanisms and management of retinopathy of prematurity. N Engl J Med 367(26):2515–2526. https://doi.org/10.1056/NEJMra1208129

3. Good WV, Group ET for R of PC (2004) Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 102:233–250. https://pubmed.ncbi.nlm.nih.gov/15747762

4. Geloneck MM, Chuang AZ, Clark WL et al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132(11):1327–1333. https://doi.org/10.1001/jamaophthalmol.2014.2772

5. Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603–615. https://doi.org/10.1056/NEJMoa1007374

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3